Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?
Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sarepta Therapeutics shares rise on positive Duchenne gene therapy data
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from its Phase 3 EMBARK study evaluating its gene therapy ELEVIDYS in ambulatory patients with Duchenne muscular dystrophy. Sarepta said patients treated with ELEVIDYS demonstrated statistically significant and clinically meaningful slowing of disease progression across key functional measures compared with an untreated external control group.
Sarepta Therapeutics: Is Elevidys A Bust?
Sarepta Therapeutics remains highly volatile as ELEVIDYS sales drive sentiment, with Q4 revenue missing expectations and safety concerns lingering. Despite fading ELEVIDYS sales, SRPT management reiterates a $500M annual revenue floor and expects normalization in ambulatory demand to support growth. SRPT fundamentals are robust, with nearly $1B in cash, no near-term debt, and a stable PMO franchise generating almost $1B in 2025 revenue.
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests
Sarepta Therapeutics is upgraded to a buy following HHS's addition of Duchenne muscular dystrophy to the newborn screening panel. Earlier DMD detection aligns perfectly with SRPT's preventative therapies, expanding the eligible patient pool and improving payer reimbursement prospects. The company recently refinanced a significant portion of its debt, extending maturities and enhancing financial flexibility despite a higher interest rate.
Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries
The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys that includes its most serious safety warning and restricts use of the treatment to walking patients with Duchenne muscular dystrophy.
